Beyond neutralization for BNT162b2 mRNA vaccination

Payal Damani-Yokota; Stephen T Yeung; Kamal M Khanna

doi:10.1016/j.chom.2021.06.013

Beyond neutralization for BNT162b2 mRNA vaccination

Cell Host Microbe. 2021 Jul 14;29(7):1033-1035. doi: 10.1016/j.chom.2021.06.013.

Authors

Payal Damani-Yokota¹, Stephen T Yeung², Kamal M Khanna³

Affiliations

¹ Department of Microbiology, New York University Langone Health, New York, NY, USA.
² Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
³ Department of Microbiology, New York University Langone Health, New York, NY, USA; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA. Electronic address: kamal.khanna@nyulangone.org.

Abstract

Mounting a robust immune response against SARS-CoV-2 requires neutralization as well as effector T cell functions. In this issue of Cell Host Microbe, Tauzin et al. characterize the humoral and T cell responses after a single dose of BNT162b2 mRNA vaccine in individuals with or without previous exposure to SARS-CoV-2.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Humans
RNA, Messenger / genetics
SARS-CoV-2*
Vaccination

Substances

COVID-19 Vaccines
RNA, Messenger
BNT162 Vaccine

Abstract

Publication types

MeSH terms

Substances

Grants and funding